AU2007328435B2 - Methods of treating hemolytic anemia - Google Patents

Methods of treating hemolytic anemia Download PDF

Info

Publication number
AU2007328435B2
AU2007328435B2 AU2007328435A AU2007328435A AU2007328435B2 AU 2007328435 B2 AU2007328435 B2 AU 2007328435B2 AU 2007328435 A AU2007328435 A AU 2007328435A AU 2007328435 A AU2007328435 A AU 2007328435A AU 2007328435 B2 AU2007328435 B2 AU 2007328435B2
Authority
AU
Australia
Prior art keywords
antibody
pnh
eculizumab
certain embodiments
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2007328435A
Other languages
English (en)
Other versions
AU2007328435A1 (en
Inventor
Leonard Bell
Russell P. Rother
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of AU2007328435A1 publication Critical patent/AU2007328435A1/en
Application granted granted Critical
Publication of AU2007328435B2 publication Critical patent/AU2007328435B2/en
Priority to AU2013206217A priority Critical patent/AU2013206217A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2007328435A 2006-11-08 2007-11-08 Methods of treating hemolytic anemia Active AU2007328435B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013206217A AU2013206217A1 (en) 2006-11-08 2013-06-07 Methods of treating hemolytic anemia

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/595,118 US20070116710A1 (en) 2004-02-03 2006-11-08 Methods of treating hemolytic anemia
US11/595,118 2006-11-08
PCT/US2007/023623 WO2008069889A2 (en) 2006-11-08 2007-11-08 Methods of treating hemolytic anemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013206217A Division AU2013206217A1 (en) 2006-11-08 2013-06-07 Methods of treating hemolytic anemia

Publications (2)

Publication Number Publication Date
AU2007328435A1 AU2007328435A1 (en) 2008-06-12
AU2007328435B2 true AU2007328435B2 (en) 2013-03-07

Family

ID=39326944

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007328435A Active AU2007328435B2 (en) 2006-11-08 2007-11-08 Methods of treating hemolytic anemia

Country Status (10)

Country Link
US (1) US20070116710A1 (enExample)
EP (1) EP2089058A2 (enExample)
JP (1) JP2010509338A (enExample)
KR (1) KR20090076960A (enExample)
AU (1) AU2007328435B2 (enExample)
BR (1) BRPI0718830A2 (enExample)
CA (1) CA2669735A1 (enExample)
IL (1) IL198320A0 (enExample)
MX (1) MX2009004986A (enExample)
WO (1) WO2008069889A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3022097C (en) 2006-03-15 2020-10-27 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
EP2006381B1 (en) 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Method for controlling blood pharmacokinetics of antibodies
PT2698166E (pt) 2006-10-10 2016-01-27 Regenesance B V Inibição do complemento para regeneração nervosa aprimorada
RU2010116245A (ru) * 2007-09-24 2011-11-10 Ноксон Фарма Аг (De) НУКЛЕИНОВЫЕ КИСЛОТЫ, СВЯЗЫВАЮЩИЕ C5a
CA2700701C (en) 2007-09-26 2020-12-29 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
WO2009097120A1 (en) * 2008-01-29 2009-08-06 Celgene Corporation Methods using immunomodulatory compounds for modulating level of cd59
NZ717429A (en) 2008-04-11 2018-07-27 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
PT2328616E (pt) * 2008-08-05 2015-08-26 Novartis Ag Composições e métodos para anticorpos dirigidos à proteína c5 do complemento
AU2009313203B2 (en) 2008-11-10 2015-08-27 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
MX2012005388A (es) 2009-11-09 2012-07-23 Alexion Pharma Inc Reactivos y metodos para detectar globulos blancos pnh tipo ii y su identificacion como factores de riesgo para transtornos trombolicos.
CN108715614A (zh) 2010-11-30 2018-10-30 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
SG11201403416TA (en) 2011-12-21 2014-07-30 Novartis Ag Compositions and methods for antibodies targeting factor p
CN104145018B (zh) 2012-01-10 2019-05-10 诺松制药股份公司 新型C5a结合性核酸
EP3046581B1 (en) * 2013-09-16 2020-04-01 Children's Hospital Medical Center Compositions and methods for treatment of hsct-associated thrombotic microangiopathy
KR102650420B1 (ko) 2014-12-19 2024-03-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
TWI617580B (zh) 2014-12-19 2018-03-11 中外製藥股份有限公司 抗ｃ５抗體及使用方法
WO2016117346A1 (en) 2015-01-22 2016-07-28 Chugai Seiyaku Kabushiki Kaisha A combination of two or more anti-c5 antibodies and methods of use
US11840564B2 (en) 2015-06-09 2023-12-12 Children's Hospital Medical Center Dosing algorithm for complement inhibitor
EP4374922A3 (en) 2016-06-14 2024-08-28 Regeneron Pharmaceuticals, Inc. Anti-c5 antibodies and uses thereof
TW202300168A (zh) 2016-08-05 2023-01-01 日商中外製藥股份有限公司 Il-8相關疾病之治療用或預防用組成物
IT201600121482A1 (it) * 2016-11-30 2018-05-30 Univ Degli Studi Di Verona Fattore H per l’uso nel trattamento e/o prevenzione della formazione di eterotrombi in pazienti affetti da anemia falciforme
KR101949891B1 (ko) 2017-01-31 2019-02-19 추가이 세이야쿠 가부시키가이샤 C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법
US12037389B2 (en) 2017-12-01 2024-07-16 Children's Hospital Medical Center Compositions for interferon blockade and methods of using same
SG11202004662RA (en) 2017-12-13 2020-06-29 Regeneron Pharma Anti-c5 antibody combinations and uses thereof
US20190247560A1 (en) 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
US20210301004A1 (en) 2018-08-01 2021-09-30 Chugai Seiyaku Kabushiki Kaisha A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
EP4003408A1 (en) 2019-07-31 2022-06-01 F. Hoffmann-La Roche AG Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab
KR20240033090A (ko) 2019-07-31 2024-03-12 에프. 호프만-라 로슈 아게 항-c5 항체 크로발리맙의 사용에 의한 c5-관련 질병의 치료 또는 예방을 위한 투여량 및 투여 섭생
CN116406287A (zh) 2020-04-16 2023-07-07 巴黎公共医疗救助机构 治疗由病毒引起的补体介导的障碍的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005074607A2 (en) * 2004-02-03 2005-08-18 Alexion Pharmaceuticals, Inc. Method of treating hemolytic disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686100A (en) * 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
US5135916A (en) * 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
DE60136656D1 (de) * 2000-12-05 2009-01-02 Alexion Pharma Inc Rationell entworfene Antikörper
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005074607A2 (en) * 2004-02-03 2005-08-18 Alexion Pharmaceuticals, Inc. Method of treating hemolytic disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRODSKY, R. A; Hematology Am Soc Hematol Educ Program. (2006), Vol 516, pages 24-28 *
HILL. A, et al; BLOOD (2005), Vol 106, No 7, pages 2559-2565 *

Also Published As

Publication number Publication date
EP2089058A2 (en) 2009-08-19
MX2009004986A (es) 2009-05-21
BRPI0718830A2 (pt) 2014-02-04
WO2008069889A3 (en) 2008-08-07
KR20090076960A (ko) 2009-07-13
US20070116710A1 (en) 2007-05-24
CA2669735A1 (en) 2008-06-12
WO2008069889A2 (en) 2008-06-12
JP2010509338A (ja) 2010-03-25
WO2008069889A9 (en) 2008-09-18
AU2007328435A1 (en) 2008-06-12
IL198320A0 (en) 2011-08-01

Similar Documents

Publication Publication Date Title
AU2007328435B2 (en) Methods of treating hemolytic anemia
AU2005209854B2 (en) Method of treating hemolytic disease
CA3022097C (en) Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
AU2013206217A1 (en) Methods of treating hemolytic anemia
HK1175988A (en) Method of treating hemolytic disease
HK1175985A (en) Method of treating hemolytic disease
HK1175989A (en) Method of treating hemolytic disease
HK1175986A (en) Method of treating hemolytic disease
HK1094950B (en) Method of treating hemolytic disease
HK1175987A (en) Method of treating hemolytic disease
HK1235319A1 (en) Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)